Concepts (129)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Epilepsy | 9 | 2024 | 113 | 1.810 |
Why?
|
| Seizures | 6 | 2023 | 141 | 1.470 |
Why?
|
| Confusion | 2 | 2019 | 16 | 1.160 |
Why?
|
| Vision Disorders | 2 | 2019 | 69 | 1.110 |
Why?
|
| Status Epilepticus | 3 | 2023 | 24 | 1.030 |
Why?
|
| Drug Resistant Epilepsy | 4 | 2024 | 17 | 0.770 |
Why?
|
| Electroencephalography | 4 | 2024 | 156 | 0.730 |
Why?
|
| Tongue | 1 | 2020 | 18 | 0.650 |
Why?
|
| Deglutition | 1 | 2020 | 20 | 0.650 |
Why?
|
| Mouth | 1 | 2020 | 36 | 0.640 |
Why?
|
| Sleep Deprivation | 1 | 2020 | 16 | 0.630 |
Why?
|
| Heart Arrest | 1 | 2021 | 177 | 0.570 |
Why?
|
| Creutzfeldt-Jakob Syndrome | 1 | 2017 | 3 | 0.520 |
Why?
|
| Psychotic Disorders | 1 | 2018 | 150 | 0.500 |
Why?
|
| Patient Readmission | 5 | 2021 | 452 | 0.480 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2017 | 113 | 0.470 |
Why?
|
| Hospitalization | 4 | 2020 | 1403 | 0.460 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2016 | 126 | 0.460 |
Why?
|
| Kidney Neoplasms | 1 | 2017 | 173 | 0.450 |
Why?
|
| Fibrinolytic Agents | 1 | 2016 | 183 | 0.440 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 712 | 0.320 |
Why?
|
| Stroke | 3 | 2020 | 1225 | 0.290 |
Why?
|
| Treatment Outcome | 3 | 2023 | 5830 | 0.270 |
Why?
|
| Humans | 21 | 2024 | 65826 | 0.260 |
Why?
|
| Retrospective Studies | 6 | 2023 | 6953 | 0.240 |
Why?
|
| Risk Factors | 6 | 2021 | 5471 | 0.220 |
Why?
|
| New York | 2 | 2021 | 144 | 0.200 |
Why?
|
| Middle Aged | 8 | 2020 | 18491 | 0.200 |
Why?
|
| Epilepsies, Partial | 1 | 2023 | 18 | 0.190 |
Why?
|
| Databases, Factual | 4 | 2020 | 888 | 0.190 |
Why?
|
| Pseudomonas aeruginosa | 2 | 2016 | 132 | 0.190 |
Why?
|
| Aged | 8 | 2020 | 15141 | 0.180 |
Why?
|
| Comorbidity | 3 | 2021 | 1122 | 0.170 |
Why?
|
| Female | 10 | 2024 | 34414 | 0.170 |
Why?
|
| First Aid | 1 | 2020 | 6 | 0.160 |
Why?
|
| Cross-Over Studies | 1 | 2021 | 163 | 0.160 |
Why?
|
| International Classification of Diseases | 2 | 2018 | 136 | 0.160 |
Why?
|
| Brain Stem Infarctions | 1 | 2020 | 4 | 0.160 |
Why?
|
| Pons | 1 | 2020 | 15 | 0.160 |
Why?
|
| Coma | 1 | 2020 | 18 | 0.160 |
Why?
|
| Bacterial Proteins | 3 | 2016 | 741 | 0.160 |
Why?
|
| Retinal Artery Occlusion | 1 | 2020 | 5 | 0.160 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2021 | 162 | 0.150 |
Why?
|
| Aged, 80 and over | 3 | 2018 | 5681 | 0.140 |
Why?
|
| Multiple Sclerosis | 1 | 2021 | 227 | 0.140 |
Why?
|
| Lorazepam | 1 | 2018 | 8 | 0.140 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2018 | 14 | 0.140 |
Why?
|
| Public Health | 1 | 2020 | 188 | 0.140 |
Why?
|
| Hypnotics and Sedatives | 1 | 2018 | 66 | 0.140 |
Why?
|
| Liver Cirrhosis | 1 | 2020 | 184 | 0.130 |
Why?
|
| Male | 8 | 2024 | 31398 | 0.130 |
Why?
|
| Evidence-Based Medicine | 1 | 2020 | 464 | 0.130 |
Why?
|
| Mood Disorders | 1 | 2018 | 79 | 0.130 |
Why?
|
| Patient Discharge | 2 | 2018 | 522 | 0.130 |
Why?
|
| Suicide, Attempted | 1 | 2018 | 111 | 0.130 |
Why?
|
| Fatal Outcome | 1 | 2017 | 122 | 0.130 |
Why?
|
| United States | 5 | 2024 | 8190 | 0.130 |
Why?
|
| Child | 5 | 2024 | 4653 | 0.120 |
Why?
|
| Cerebral Cortex | 1 | 2018 | 276 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2024 | 2324 | 0.120 |
Why?
|
| Drug Resistance, Multiple | 1 | 2016 | 28 | 0.120 |
Why?
|
| Adult | 7 | 2023 | 17567 | 0.120 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 746 | 0.120 |
Why?
|
| Brain Ischemia | 2 | 2020 | 423 | 0.120 |
Why?
|
| Type III Secretion Systems | 1 | 2016 | 3 | 0.120 |
Why?
|
| Salmonella typhimurium | 1 | 2016 | 86 | 0.120 |
Why?
|
| Regression Analysis | 1 | 2016 | 498 | 0.110 |
Why?
|
| Analysis of Variance | 1 | 2016 | 606 | 0.110 |
Why?
|
| Antigens, Bacterial | 1 | 2016 | 202 | 0.110 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2016 | 218 | 0.110 |
Why?
|
| Colonic Neoplasms | 1 | 2016 | 220 | 0.110 |
Why?
|
| Metal Nanoparticles | 1 | 2016 | 191 | 0.100 |
Why?
|
| Cell Membrane | 2 | 2016 | 506 | 0.090 |
Why?
|
| Positron-Emission Tomography | 2 | 2024 | 233 | 0.090 |
Why?
|
| Registries | 1 | 2016 | 934 | 0.090 |
Why?
|
| Pore Forming Cytotoxic Proteins | 1 | 2011 | 34 | 0.090 |
Why?
|
| Liposomes | 1 | 2011 | 118 | 0.080 |
Why?
|
| Pseudomonas Infections | 1 | 2011 | 73 | 0.080 |
Why?
|
| Molecular Chaperones | 1 | 2011 | 100 | 0.080 |
Why?
|
| Time Factors | 1 | 2016 | 3778 | 0.070 |
Why?
|
| Surveys and Questionnaires | 2 | 2024 | 2790 | 0.060 |
Why?
|
| Animals | 2 | 2020 | 21489 | 0.050 |
Why?
|
| Censuses | 1 | 2023 | 18 | 0.050 |
Why?
|
| Monitoring, Physiologic | 1 | 2023 | 170 | 0.050 |
Why?
|
| Health Facilities | 1 | 2022 | 46 | 0.050 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2022 | 206 | 0.040 |
Why?
|
| Hematoma, Subdural | 1 | 2020 | 10 | 0.040 |
Why?
|
| Hernia | 1 | 2020 | 14 | 0.040 |
Why?
|
| Hepatorenal Syndrome | 1 | 2020 | 2 | 0.040 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2020 | 15 | 0.040 |
Why?
|
| Ascites | 1 | 2020 | 22 | 0.040 |
Why?
|
| Hepatic Encephalopathy | 1 | 2020 | 10 | 0.040 |
Why?
|
| Palliative Care | 1 | 2022 | 251 | 0.040 |
Why?
|
| Peritonitis | 1 | 2020 | 43 | 0.040 |
Why?
|
| Research Design | 1 | 2022 | 590 | 0.040 |
Why?
|
| Protein Binding | 2 | 2016 | 1637 | 0.040 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2020 | 88 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2020 | 420 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2020 | 579 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2021 | 745 | 0.030 |
Why?
|
| Thrombolytic Therapy | 1 | 2020 | 205 | 0.030 |
Why?
|
| Length of Stay | 1 | 2020 | 828 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2016 | 98 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2016 | 108 | 0.030 |
Why?
|
| Lipid Bilayers | 1 | 2016 | 53 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2016 | 115 | 0.030 |
Why?
|
| Prevalence | 1 | 2020 | 1453 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2016 | 326 | 0.030 |
Why?
|
| Disease Progression | 1 | 2020 | 1229 | 0.030 |
Why?
|
| Protein Multimerization | 1 | 2016 | 181 | 0.030 |
Why?
|
| Smoking | 1 | 2020 | 864 | 0.030 |
Why?
|
| Cell Death | 1 | 2016 | 289 | 0.030 |
Why?
|
| Depression | 1 | 2021 | 910 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2016 | 541 | 0.030 |
Why?
|
| Gold | 1 | 2016 | 235 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 2496 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2016 | 1044 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2018 | 2649 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 1573 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2011 | 89 | 0.020 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2011 | 94 | 0.020 |
Why?
|
| Bacterial Toxins | 1 | 2011 | 58 | 0.020 |
Why?
|
| Models, Biological | 1 | 2016 | 1193 | 0.020 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2011 | 84 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2018 | 3339 | 0.020 |
Why?
|
| Biological Transport | 1 | 2011 | 292 | 0.020 |
Why?
|
| Protein Transport | 1 | 2011 | 405 | 0.020 |
Why?
|
| Cryoelectron Microscopy | 1 | 2011 | 218 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 2329 | 0.020 |
Why?
|